Curie Institute (Paris)

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

Retrieved on: 
Tuesday, April 9, 2024
PDT, Chemoradiotherapy, Head, Disease, Intelligence, Patient, Neoplasm, Health care, Cancer, AI, AACR, NEC, Curie Institute (Paris), Euronext Paris, Poster, Corporation, Neck, Vaccine

Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.

Key Points: 
  • Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.
  • These data are highlighted in the AACR press conference being held today and in a poster presentation which will take place tomorrow, April 10, at 9:00 a.m. PDT.
  • Key findings of the poster include:
    All 16 patients who received TG4050 are disease free after a median 18.6-month follow-up.
  • TG4050 is now starting to show a potential benefit for head and neck cancer patients at high risk of relapse.

ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie

Retrieved on: 
Monday, March 25, 2024
Cloud, RB1, Hydrolysis, Irinotecan, Progression-free survival, Patient, SAN, Biomarker, Research, DNA, Cancer, Cmax, SN-38, Clinical trial, Curie Institute (Paris), Safety, Prodrug, Homologous recombination, ADC, TNBC, Teaching, PEG

Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).

Key Points: 
  • Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).
  • The TOPOLOGY trial is run by Institut Curie (Paris and Saint Cloud, France), with principal investigator Prof. Francois-Clement Bidard .
  • PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC.
  • Institut Curie has 3 sites (Paris, Saint-Cloud and Orsay) with over 3,700 health professionals working on treatment, research and teaching ([email protected]) Information on this clinical trial is available at clinicaltrials.gov, NCT06162351.

Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology

Retrieved on: 
Monday, March 4, 2024
Stem Cells, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Medical Devices, Other Health, Liver, CD3, Toxicity, MAIT, Neoplasm, Immunotherapy, Curie Institute (Paris), Lung, Risk, Antibody, Lymphocyte, Patient, Medication, Tissue, Research, Cancer, Vaccine

This agreement covers the development of a new class of antibodies, capable of specifically targeting and engaging MAIT cells to kill cancer cells.

Key Points: 
  • This agreement covers the development of a new class of antibodies, capable of specifically targeting and engaging MAIT cells to kill cancer cells.
  • Biomunex, which was already co-inventor and a 50% co-owner of this unique innovative approach, now holds full worldwide rights.
  • In addition, MAIT cells present the MDR-12 protein on their surface, providing them with a natural resistance to some major chemotherapies.
  • “The research performed at Institut Curie has led to a major discovery which now opens up promising new therapeutic options.

High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies

Retrieved on: 
Tuesday, January 30, 2024
Transfer, Partnership, Curie Institute (Paris), Cell, AI, Immunotherapy, DNA, Research, Rupture, Patient, TREX1, Artificial intelligence, Drug design, Ligand, CNRS, Protein, HPC, Biology, Metastasis, University, Cancer

High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies.

Key Points: 
  • High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies.
  • These will then be biologically validated and biochemically characterized by Institut Curie and the University of Bordeaux respectively.
  • This collaborative approach reflects the shared commitment of Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux to explore innovative approaches to the development of more targeted and effective cancer therapies.
  • We are delighted and honored to be working with the Institut Curie & the University of Bordeaux along these lines."

One Biosciences Partners With AP-HP to Launch a Single-cell Research Project on a Rare Kidney Disease

Retrieved on: 
Friday, November 10, 2023
Research, Assistance Publique–Hôpitaux de Paris, Transplant, AP-HP, Kidney disease, Disease, AI, A.I, Patient, Medicine, Creative Biolabs, Heart, Partnership, Syndrome, Biomarker, Sorbonne University, Hospital, Silla, Curie Institute (Paris), Single-cell analysis, Pharmaceutical industry, News

PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.

Key Points: 
  • PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.
  • A condition characterized by a gradual loss of kidney function over time, this particular disease has no viable therapeutic option to date and transplantation is often the only alternative, despite frequent relapses.
  • One Biosciences will leverage the data to identify new therapeutic targets in this rare kidney disease in order to develop precision medicines and biomarkers of a relapse of the disease via its discovery platform.
  • This is an important milestone, and I'd like to thank our partners for their commitment," said Hedi Ben Brahim, CEO of One Biosciences.

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Retrieved on: 
Tuesday, December 12, 2023
CNS, Stomatitis, BTK, History, Patient, PCNSL, BID, Symantec Endpoint Protection, Non-Hodgkin lymphoma, Infrared spectroscopy correlation table, NHL, Syncope, Pharmaceutical industry, Curie Institute (Paris)

LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.

Key Points: 
  • LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.
  • "We are very pleased with the initial emavusertib/ibrutinib combination data from the TakeAim Lymphoma study.
  • As of October 12th, the TakeAim Lymphoma trial has enrolled and treated 19 Non-Hodgkin Lymphoma (NHL) patients, with a combination of emavusertib and ibrutinib; with emavusertib doses ranging from 100 mg to 300 mg BID.
  • These data underscore the potential of emavusertib to re-sensitize patients to BTKi therapy, marking a significant advancement in Non-Hodgkin Lymphoma treatment.

One Biosciences announces the appointment of Hedi Ben Brahim as Chief Executive Officer

Retrieved on: 
Thursday, September 7, 2023
Vaccine, TNG, Drug development, Single-cell analysis, Immunotherapy, Chinese Institute of Certified Public Accountants, Curie Institute (Paris), Science, Public sector, Ministry, Ministry of Social Affairs, Ministry of Social Affairs and Health, Home, Patient, Biology, Economy, Management, Pharmaceutical industry, Health, Vallourec, Euronext, Transgene

Hedi is a recognized leader in the biotechnology industry, joining from Transgene (Euronext: TNG) where he served as Chief Executive Officer.

Key Points: 
  • Hedi is a recognized leader in the biotechnology industry, joining from Transgene (Euronext: TNG) where he served as Chief Executive Officer.
  • His appointment is in line with Home Biosciences’ venture builder business model and majority shareholder position and serves as foundation for One Biosciences’ forthcoming series A financing.
  • He replaces Mrs. Magali Richard, who has served as CEO of One Biosciences, being co-founder of the Company and deputy CEO of Home Biosciences.
  • She will transition to Chief Operating Officer (COO) of One Biosciences, supporting Hedi in his onboarding.

One Biosciences announces the appointment of Hedi Ben Brahim as Chief Executive Officer

Retrieved on: 
Thursday, September 7, 2023
Vaccine, TNG, Drug development, Single-cell analysis, Immunotherapy, Chinese Institute of Certified Public Accountants, Curie Institute (Paris), Science, Public sector, Ministry, Ministry of Social Affairs, Ministry of Social Affairs and Health, Home, Patient, Biology, Economy, Management, Pharmaceutical industry, Health, Vallourec, Euronext, Transgene

Hedi is a recognized leader in the biotechnology industry, joining from Transgene (Euronext: TNG) where he served as Chief Executive Officer.

Key Points: 
  • Hedi is a recognized leader in the biotechnology industry, joining from Transgene (Euronext: TNG) where he served as Chief Executive Officer.
  • His appointment is in line with Home Biosciences’ venture builder business model and majority shareholder position and serves as foundation for One Biosciences’ forthcoming series A financing.
  • He replaces Mrs. Magali Richard, who has served as CEO of One Biosciences, being co-founder of the Company and deputy CEO of Home Biosciences.
  • She will transition to Chief Operating Officer (COO) of One Biosciences, supporting Hedi in his onboarding.

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%

Retrieved on: 
Thursday, June 29, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Carcinoma, Bristol Myers Squibb, Human, The New England Journal of Medicine, Civil service commission, Neoplasm, Cancer, Research, Curie Institute (Paris), Lung cancer, Immunotherapy, PCR, BMY, EMA, European Commission, Patient, Checkmate, Risk, Melanoma, European, EFS, Recurrence, EC, Death, PD-L1, NYSE, Disease, Paris-Saclay University, Pharmaceutical industry, EU, NSCLC, Nivolumab

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%.
  • With this EC decision, Opdivo with chemotherapy becomes the first neoadjuvant immunotherapy-based treatment option approved for patients in the European Union (EU) in this setting.
  • The safety profile of Opdivo with chemotherapy was consistent with previously reported studies in NSCLC.
  • “Although we have seen progress in the treatment of earlier-stage non-small cell lung cancer, a significant number of people still face poor outcomes.

Bionano Reports First Quarter 2023 Results and Highlights Recent Business Progress

Retrieved on: 
Tuesday, May 9, 2023
HRD, Genomics, GAAP, Curie Institute (Paris), Doctor of Philosophy, Acquisition, Investment, Risk, DSM-IV codes, Bone marrow, University, NGS, Spectrum, Mosaic, Research, Whole genome sequencing, LRS, Children's Hospital Los Angeles, WGS, Growth, Hospital, OEM, OGM, NMPA, Trisomy, Total, BGPT, MRKH, DNA, Workflow, Cancer, SOC, Publication, Genetic disorder, Standard of care, University of Toronto, ASD, SAN, National Medical Products Administration, IVD, MD Anderson Cancer Center, Acceleration, Toronto, SVS, Sale, NVIDIA, Female, Breast cancer, Mobile phone, Video game, Medical device, Pharmaceutical industry, Dietary supplement, Renewable energy, Augusta University

GAAP gross margin for the first quarter of 2023 was 28%, compared to 15% from the first quarter of 2022.

Key Points: 
  • GAAP gross margin for the first quarter of 2023 was 28%, compared to 15% from the first quarter of 2022.
  • First quarter 2023 non-GAAP¹ gross margin was 30%, compared to 15% from the first quarter of 2022.
  • First quarter 2023 GAAP operating expense was $39.9 million, compared to $30.8 million in the first quarter of 2022.
  • First quarter 2023 non-GAAP operating expense was $33.6 million, compared to $24.2 million in the first quarter of 2022.